BridgeBio Pharma, Inc.(BBIO)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

BBIO BridgeBio Pharma, Inc.

已收盘 12-19 16:00:00 EST

26.21

+0.23

+0.89%

盘后26.00

-0.21-0.80%

19:42 EST

最高26.61	最低25.34	成交量246.55万
今开26.08	昨收25.98	日振幅4.87%
总市值49.53亿	流通市值33.66亿	总股本1.89亿
成交额6,432万	换手率1.92%	流通股本1.28亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"BBIO","market":"US","secType":"STK","nameCN":"BridgeBio Pharma, Inc.","latestPrice":26.21,"timestamp":1734642000000,"preClose":25.98,"halted":0,"volume":2465541,"hourTrading":{"tag":"盘后","latestPrice":26,"preClose":26.21,"latestTime":"19:42 EST","volume":57096,"amount":1496034.475042,"timestamp":1734655348770},"delay":0,"floatShares":128424863,"shares":188989802,"eps":-2.406907,"marketStatus":"已收盘","marketStatusCode":5,"change":0.23,"latestTime":"12-19 16:00:00 EST","open":26.08,"high":26.605,"low":25.34,"amount":64324145.120742,"amplitude":0.048691,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.406907,"exchange":"NASDAQ","tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1734685200000},"adr":0,"listingDate":1561608000000,"adjPreClose":25.98,"preHourTrading":{"tag":"盘前","latestPrice":26.25,"preClose":25.98,"latestTime":"09:23 EST","volume":2671,"amount":69861.27105400001,"timestamp":1734618210549},"postHourTrading":{"tag":"盘后","latestPrice":26,"preClose":26.21,"latestTime":"19:42 EST","volume":57096,"amount":1496034.475042,"timestamp":1734655348770},"volumeRatio":1.300884,"impliedVol":0.6021,"impliedVolPercentile":0.2778},"requestUrl":"/m/hq/s/BBIO","defaultTab":"news","newsList":[{"id":"2491706330","title":"Bridgebio Pharma, Inc.盘中异动 下午盘快速跳水5.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2491706330","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491706330?lang=zh_cn&edition=full","pubTime":"2024-12-13 02:25","pubTimestamp":1734027900,"startTime":"0","endTime":"0","summary":"北京时间2024年12月13日02时25分，Bridgebio Pharma, Inc.股票出现波动，股价大幅跳水5.04%。Bridgebio Pharma, Inc.股票所在的生物技术行业中，整体跌幅为1.09%。其相关个股中，Trevi Therapeutics, Inc.、Palisade Bio, Inc.、Cero Therapeutics Holdings Inc C/Wts 13/02/2029 涨幅较大，Palisade Bio, Inc.、Aptevo Therapeutics Inc.、Conduit Pharmaceuticals Inc.较为活跃，换手率分别为3924.05%、1067.88%、89.78%，振幅较大的相关个股有Neurosense Therapeutics Ltd C/Wts 10/11/2026 、Palisade Bio, Inc.、Aptevo Therapeutics Inc.，振幅分别为129.16%、99.29%、95.90%。Bridgebio Pharma, Inc.公司简介：BridgeBio Pharma是一家生物技术公司，专注于发现、开发、测试和提供针对遗传疾病患者的变革性治疗方法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241213022500a1e9b887&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241213022500a1e9b887&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4585","BK4139","BK4588","BBIO","BK4505"],"gpt_icon":0},{"id":"2489285237","title":"Bridgebio Pharma, Inc.盘中异动 早盘股价大涨5.03%报28.00美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2489285237","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2489285237?lang=zh_cn&edition=full","pubTime":"2024-12-06 23:57","pubTimestamp":1733500667,"startTime":"0","endTime":"0","summary":"北京时间2024年12月06日23时57分，Bridgebio Pharma, Inc.股票出现异动，股价大幅拉升5.03%。截至发稿，该股报28.00美元/股，成交量27.9448万股，换手率0.15%，振幅5.36%。Bridgebio Pharma, Inc.股票所在的生物技术行业中，整体涨幅为0.68%。Bridgebio Pharma, Inc.公司简介：BridgeBio Pharma是一家生物技术公司，专注于发现、开发、测试和提供针对遗传疾病患者的变革性治疗方法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241206235747ab630171&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241206235747ab630171&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4588","BBIO","BK4505","BK4585"],"gpt_icon":0},{"id":"2486063108","title":"美国研究综述-多米诺比萨、弹性 NV、雪花","url":"https://stock-news.laohu8.com/highlight/detail?id=2486063108","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486063108?lang=zh_cn&edition=full","pubTime":"2024-11-26 05:38","pubTimestamp":1732570699,"startTime":"0","endTime":"0","summary":"美国研究综述-多米诺比萨、弹性 NV、雪花路透社11月25日 - 华尔街证券分析师周一调整了对多米诺比萨、Elastic NV 和 Snowflake 等几家美国上市公司的评级和目标价。要点 * 多米诺比萨公司DPZ.N：TD Cowen将目标价从475美元上调至515美元 * Elastic NV ESTC.N：Wedbush将其评级从 \"中性 \"上调至 \"跑赢大盘\"。* Thor Industries Inc THO.N：CFRA将目标价从90美元上调至115美元 以下是路透社周一报导的美国公司研究报告摘要。* Edwards Lifesciences Corp EW.N：Leerink Partners将目标价从73美元上调至74美元 * Ehealth Inc","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241125:nL3T3MW0XP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DXCM","AKR","CYH","EW","CRL","ADVM","BK4106","EWCZ","CCAP","LU2211817866.USD","CSWI","DASH","AMGN","COLB","EHC","LU1861559042.SGD","BURL","BK","DXLG","BK4581","KR","LU0345770993.USD","BBIO","BK4505","BJ","CHWY","DTM","EDIT","CFLT","AZEK","DE","ACHC","BERY","LU1429558221.USD","LU1548497426.USD","ESTC","BKR","BMRN","CVS","LU0072461881.USD","ASH","CARM","EQT","LU2125909759.SGD","DPZ"],"gpt_icon":1},{"id":"2486503315","title":"Bridgebio Pharma, Inc.盘中异动 股价大涨21.90%报28.55美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2486503315","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486503315?lang=zh_cn&edition=full","pubTime":"2024-11-25 22:31","pubTimestamp":1732545096,"startTime":"0","endTime":"0","summary":"北京时间2024年11月25日22时31分，Bridgebio Pharma, Inc.股票出现波动，股价急速拉升21.90%。Bridgebio Pharma, Inc.股票所在的生物技术行业中，整体涨幅为0.92%。其相关个股中，Scholar Rock Holding Corporation、Citius Pharmaceuticals, Inc.、Bridgebio Pharma, Inc.涨幅较大，Cognition Therapeutics, Inc.、木薯科学、Citius Pharmaceuticals, Inc.较为活跃，换手率分别为85.54%、52.88%、33.80%，振幅较大的相关个股有Werewolf Therapeutics, Inc.、Kodiak Sciences Inc、Celcuity Inc.，振幅分别为103.16%、102.58%、102.58%。Bridgebio Pharma, Inc.公司简介：BridgeBio Pharma Inc 参与确定用于治疗孟德尔病患者的先进变革性药物，以及具有明确基因驱动因素的癌症。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241125223136a2548bdb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241125223136a2548bdb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4585","BK4505","BBIO","BK4588"],"gpt_icon":0},{"id":"2485418562","title":"美国 FDA 批准 BridgeBio 公司生产治疗罕见心脏病的药物","url":"https://stock-news.laohu8.com/highlight/detail?id=2485418562","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485418562?lang=zh_cn&edition=full","pubTime":"2024-11-23 08:21","pubTimestamp":1732321272,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 ))    路透11月23日 - 美国食品和药物管理局已批准了BridgeBio公司  治疗一种罕见致命心脏病的药物，该公司周五表示，这使它成为辉瑞  大片Vyndaqel主导的市场上的第一种新疗法。这种口服药物的品牌为Attruby，被批准用于治疗患有转甲状腺素淀粉样心肌病的成年患者(ATTR-CM)，这种病的转甲状腺素蛋白在心脏中积聚，可导致器官衰竭。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4548","BK4585","BK4505","BK4139","PFE","BK4588","ALNY","BBIO"],"gpt_icon":0},{"id":"2484715456","title":"美国研究综述-Apellis Pharmaceuticals、Energizer Holdings、沃尔玛","url":"https://stock-news.laohu8.com/highlight/detail?id=2484715456","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484715456?lang=zh_cn&edition=full","pubTime":"2024-11-20 14:56","pubTimestamp":1732085774,"startTime":"0","endTime":"0","summary":"    路透11月20日 - 华尔街证券分析师周三调整了对几家美国上市公司的评级和目标价，其中包括 Apellis Pharmaceuticals、Energizer Holdings 和沃尔玛。要闻              * Apellis Pharmaceuticals Inc   ：摩根大通将目标价从57美元下调至50美元             * Chord Energy Corp   ：加拿大皇家银行将目标价从185美元下调至180美元             * Energizer Holdings Inc   ：摩根大通将其评级从 \"减持 \"上调至 \"中性\"。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IIIV","LU0265550946.USD","BK4528","FSUN","VERA","CHRD","LU2430703251.USD","NOG","BK4187","MNPR","VIR","LU1267930490.SGD","ABUS","LH","DYN","AVAV","PIII","CASY","CRM","LU2286300806.USD","ANNX","OLMA","BK4579","IE00B19Z8X17.USD","LU1066053197.SGD","BK4086","LU1951198990.SGD","IE00BZ1G4Q59.USD","LU0310799852.SGD","SWTX","NUVL","LU0528227936.USD","BBIO","ENR","APLS","BK4505","LU2756315318.SGD","LU1551013425.SGD","LOW","AZEK","VVV","BERY","OCSL","LU1988902786.USD","LU0006061336.USD","TVTX","BK4596","BRBR","WMT","PBF"],"gpt_icon":0},{"id":"2484891658","title":"Bridgebio Pharma, Inc.2024财年第三财季实现净利润-1.62亿美元，同比增加8.47%","url":"https://stock-news.laohu8.com/highlight/detail?id=2484891658","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484891658?lang=zh_cn&edition=full","pubTime":"2024-11-19 18:00","pubTimestamp":1732010416,"startTime":"0","endTime":"0","summary":"11月19日，Bridgebio Pharma, Inc.公布财报，公告显示公司2024财年第三财季净利润为-1.62亿美元，同比增加8.47%；其中营业收入为2.73百万美元，同比减少33.25%，每股基本收益为-0.86美元。从资产负债表来看，Bridgebio Pharma, Inc.总负债18.83亿美元，其中短期债务4.60百万美元，资产负债比为0.36，流动比率为3.21。机构评级：截至2024年11月19日，当前有14家机构对Bridgebio Pharma, Inc.目标价做出预测，其中目标均价为47.93美元，其中最低目标价为37.00美元，最高目标价为70.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241119180025abcede9d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241119180025abcede9d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BBIO"],"gpt_icon":0},{"id":"2484983799","title":"Bridgebio Pharma, Inc.盘中异动 下午盘急速下跌5.10%报22.51美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2484983799","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484983799?lang=zh_cn&edition=full","pubTime":"2024-11-19 04:16","pubTimestamp":1731960993,"startTime":"0","endTime":"0","summary":"北京时间2024年11月19日04时16分，Bridgebio Pharma, Inc.股票出现异动，股价大幅跳水5.10%。Bridgebio Pharma, Inc.股票所在的生物技术行业中，整体涨幅为0.09%。其相关个股中，Hcw Biologics Inc.、冠科美博、Apollomics Inc C/Wts 01/04/2028 涨幅较大，冠科美博、Hcw Biologics Inc.、Tharimmune, Inc.较为活跃，换手率分别为1485.81%、1316.96%、581.36%，振幅较大的相关个股有Hcw Biologics Inc.、冠科美博、Apollomics Inc C/Wts 01/04/2028 ，振幅分别为563.48%、221.58%、193.44%。Bridgebio Pharma, Inc.公司简介：BridgeBio Pharma Inc 参与确定用于治疗孟德尔病患者的先进变革性药物，以及具有明确基因驱动因素的癌症。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024111904163398e4355a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024111904163398e4355a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4588","BK4139","BK4505","BBIO","BK4585"],"gpt_icon":0},{"id":"2483082300","title":"美国研究综述-AMN 医疗保健服务公司、Chart Industries 公司、家得宝公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2483082300","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483082300?lang=zh_cn&edition=full","pubTime":"2024-11-13 19:30","pubTimestamp":1731497406,"startTime":"0","endTime":"0","summary":"    路透11月13日 - 华尔街证券分析师周三调整了对几家美国上市公司的评级和目标价，其中包括 AMN 医疗保健服务公司、Chart Industries 公司和家得宝公司。* 908 Devices Inc   ：Leerink Partners将目标价从12美元下调至4美元             * 908 Devices Inc   ：Leerink Partners 将其目标价从 \"跑赢大盘 \"下调至 \"跑输大盘\"。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMN","DCOM","ALIT","BLFS","IRON","DOX","LU2065731478.USD","COLD","ALB","LU2133065610.SGD","AISP","BK4567","COGT","CHH","COTY","CRNX","CLF","AXSM","BK4534","CAVA","HCSG","LU0128525689.USD","DAY","LU0256863902.USD","CHGG","BHVN","BCAX","CCCS","BLTE","EWTX","HD","BK4505","DOCS","BBIO","FDX","APA","BMY","CSX","ARCH","MASS","GTLS","ABBV","ACLX","ATLC","CHRW","LU2249611893.SGD","SATS","BK4566","LU2106854487.HKD","AESI"],"gpt_icon":0},{"id":"2483031434","title":"Bridgebio Pharma, Inc.盘中异动 股价大跌5.11%报24.79美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2483031434","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483031434?lang=zh_cn&edition=full","pubTime":"2024-11-13 01:34","pubTimestamp":1731432897,"startTime":"0","endTime":"0","summary":"北京时间2024年11月13日01时34分，Bridgebio Pharma, Inc.股票出现波动，股价急速下挫5.11%。Bridgebio Pharma, Inc.股票所在的生物技术行业中，整体跌幅为0.67%。Bridgebio Pharma, Inc.公司简介：BridgeBio Pharma Inc 参与确定用于治疗孟德尔病患者的先进变革性药物，以及具有明确基因驱动因素的癌症。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241113013457971a616e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241113013457971a616e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BBIO","BK4585","BK4139","BK4588","BK4505"],"gpt_icon":0},{"id":"2482084417","title":"BridgeBio Pharma Inc 报告截至 9 月 30 日的季度业绩 - 收益摘要","url":"https://stock-news.laohu8.com/highlight/detail?id=2482084417","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482084417?lang=zh_cn&edition=full","pubTime":"2024-11-12 23:29","pubTimestamp":1731425352,"startTime":"0","endTime":"0","summary":"   * BridgeBio Pharma Inc   报告，截至9月30日的季度调整后每股亏损1.10美元，低于去年同期的每股收益1.08美元。华尔街预期为每股亏损 1.13 美元至-33 美分。* 营收同比下降 33.2%，降至 273 万美元；分析师预期为 376 万美元。* BridgeBio Pharma 公司公布的本季度每股收益为亏损 86 美分。* BridgeBio Pharma Inc 本季度股价上涨了 2.6%，今年迄今为止亏损了 35.3%。华尔街对 BridgeBio Pharma Inc 的 12 个月目标价中位数为 46.00  本摘要由 LSEG 11 月 12 日 03:28 p.m. UTC 调制解调器器生成。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"BridgeBio Pharma Inc 报告截至 9 月 30 日的季度业绩 - 收益摘要","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","BK4139","BBIO","BK4585","BK4588"],"gpt_icon":0},{"id":"2482532154","title":"Bridgebio Pharma, Inc.盘中异动 大幅拉升5.02%报27.18美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2482532154","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482532154?lang=zh_cn&edition=full","pubTime":"2024-11-09 04:54","pubTimestamp":1731099290,"startTime":"0","endTime":"0","summary":"北京时间2024年11月09日04时54分，Bridgebio Pharma, Inc.股票出现异动，股价快速拉升5.02%。Bridgebio Pharma, Inc.股票所在的生物技术行业中，整体涨幅为1.11%。其相关个股中，Psyence Biomedical Ltd C/Wts 25/01/2029、Rigel Pharmaceuticals, Inc.、Celularity Inc C/Wts 16/07/2026 涨幅较大，Elevai Labs, Inc.、Cyclacel Pharmaceuticals, Inc.、Lipella Pharmaceuticals Inc.较为活跃，换手率分别为836.66%、122.04%、89.82%，振幅较大的相关个股有Celularity Inc C/Wts 16/07/2026 、60 Degrees Pharmaceuticals Inc C/Wts 12/07/2028 、Psyence Biomedical Ltd C/Wts 25/01/2029，振幅分别为134.44%、107.20%、87.00%。Bridgebio Pharma, Inc.公司简介：BridgeBio Pharma Inc 参与确定用于治疗孟德尔病患者的先进变革性药物，以及具有明确基因驱动因素的癌症。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241109045450971a5743&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241109045450971a5743&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4585","BBIO","BK4505","BK4588","BK4139"],"gpt_icon":0},{"id":"2482703482","title":"BridgeBio Pharma Inc   预计每股亏损98美分 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2482703482","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482703482?lang=zh_cn&edition=full","pubTime":"2024-11-09 01:07","pubTimestamp":1731085644,"startTime":"0","endTime":"0","summary":"   * BridgeBio Pharma Inc    预计将在11月11日公布截至2024年9月30日的业绩报告时显示季度收入下降(预计)    * 根据LSEG的数据，12位分析师的平均预期显示，这家总部位于加利福尼亚州帕洛阿尔托的公司的营收将从去年同期的409万美元降至376.2万美元，降幅为8.1%。* LSEG 分析师对 BridgeBio Pharma Inc 的平均预期是每股亏损 98 美分。* 华尔街对 BridgeBio Pharma Inc 的 12 个月目标价中位数为 46.00 美元，高于其最新收盘价 25.88 美元。11月8日 - 上一季度业绩。除非另有说明，否则所有数据均以美元为单位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"BridgeBio Pharma Inc   预计每股亏损98美分 - 财报前瞻","news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BBIO"],"gpt_icon":0},{"id":"2480882378","title":"Bridgebio Pharma, Inc.盘中异动 早盘大幅拉升5.47%","url":"https://stock-news.laohu8.com/highlight/detail?id=2480882378","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480882378?lang=zh_cn&edition=full","pubTime":"2024-11-01 21:46","pubTimestamp":1730468813,"startTime":"0","endTime":"0","summary":"北京时间2024年11月01日21时46分，Bridgebio Pharma, Inc.股票出现异动，股价急速拉升5.47%。Bridgebio Pharma, Inc.股票所在的生物技术行业中，整体涨幅为1.11%。其相关个股中，Tc Biopharm  Plc C/Wts 10/02/2028 、Theriva Biologics, Inc.、Athira Pharma, Inc.涨幅较大，Theriva Biologics, Inc.、Athira Pharma, Inc.、Elevai Labs, Inc.较为活跃，换手率分别为2474.54%、229.80%、107.40%，振幅较大的相关个股有Klotho Neurosciences Inc C/Wts 21/06/2029 、Gri Bio, Inc.、Theriva Biologics, Inc.，振幅分别为99.00%、37.69%、36.98%。Bridgebio Pharma, Inc.公司简介：BridgeBio Pharma Inc 参与确定用于治疗孟德尔病患者的先进变革性药物，以及具有明确基因驱动因素的癌症。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241101214653a2095ab0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241101214653a2095ab0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4505","BK4585","BK4588","BBIO"],"gpt_icon":0},{"id":"2476946982","title":"Bridgebio Pharma, Inc.盘中异动 股价大涨5.03%报26.66美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2476946982","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2476946982?lang=zh_cn&edition=full","pubTime":"2024-10-17 00:11","pubTimestamp":1729095077,"startTime":"0","endTime":"0","summary":"北京时间2024年10月17日00时11分，Bridgebio Pharma, Inc.股票出现异动，股价大幅拉升5.03%。截至发稿，该股报26.66美元/股，成交量61.7019万股，换手率0.33%，振幅4.02%。Bridgebio Pharma, Inc.股票所在的生物技术行业中，整体跌幅为0.46%。Bridgebio Pharma, Inc.公司简介：BridgeBio Pharma Inc 参与确定用于治疗孟德尔病患者的先进变革性药物，以及具有明确基因驱动因素的癌症。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241017001118a1e12404&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241017001118a1e12404&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4585","BBIO","BK4139","BK4505","BK4588"],"gpt_icon":0},{"id":"2475035721","title":"美国研究综述-Affirm Holdings、Aptargroup、卡特彼勒","url":"https://stock-news.laohu8.com/highlight/detail?id=2475035721","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2475035721?lang=zh_cn&edition=full","pubTime":"2024-10-14 19:23","pubTimestamp":1728904997,"startTime":"0","endTime":"0","summary":"    路透10月14日 - 华尔街证券分析师周一调整了对几家美国上市公司的评级和目标价，其中包括 Affirm Holdings、Aptargroup 和 Caterpillar。* Aptargroup Inc   ：杰富瑞将其评级从 \"持有 \"上调至 \"买入 * 卡特彼勒公司   ：摩根士丹利将其评级从 \"等权重 \"下调至 \"减持\"。* Affirm Holdings Inc   ：Wedbush将其评级从 \"跑输大市 \"上调至 \"中性\"。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"599547af4911ad522b59f6af62f88061","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4022","CNX","LU0385154629.USD","UPST","T","CVX","DAY","ATR","DEA","EW","LU0820561909.HKD","COTY","LU1074936037.SGD","FLUT","LU0731783048.USD","IT","FANG","BLK","EXPD","LNT","DAL","BK","AFRM","XRAY","BOOT","BEN","ALNY","BBIO","BSVN","CC","EXLS","LLY","LU0868494708.USD","BK4141","CCK","CNK","FE","AB","ARCB","CCI","ALGN","BK4149","CAT","DECK","FAST","LU0203345920.USD","NVST","ASTH","AMT"],"gpt_icon":1},{"id":"2474020529","title":"Bridgebio Pharma, Inc.盘中异动 下午盘急速跳水5.01%报23.49美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2474020529","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2474020529?lang=zh_cn&edition=full","pubTime":"2024-10-10 03:29","pubTimestamp":1728502179,"startTime":"0","endTime":"0","summary":"北京时间2024年10月10日03时29分，Bridgebio Pharma, Inc.股票出现异动，股价大幅下挫5.01%。Bridgebio Pharma, Inc.股票所在的生物技术行业中，整体跌幅为0.12%。其相关个股中，Sab Biotherapeutics Inc C/Wts 22/10/2026 、Apollomics Inc C/Wts 01/04/2028 、Nutriband Inc C/Wts 涨幅较大，Windtree Therapeutics, Inc.、Aditxt, Inc.、Inhibikase Therapeutics, Inc.较为活跃，换手率分别为728.93%、600.12%、252.27%，振幅较大的相关个股有Psyence Biomedical Ltd C/Wts 25/01/2029、Coeptis Therapeutics Holdings Inc C/Wts 31/12/2024 、Inhibikase Therapeutics, Inc.，振幅分别为108.00%、73.66%、64.70%。Bridgebio Pharma, Inc.公司简介：BridgeBio Pharma Inc 参与确定用于治疗孟德尔病患者的先进变革性药物，以及具有明确基因驱动因素的癌症。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024101003293998e3b86c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024101003293998e3b86c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4588","BBIO","BK4505","BK4585","BK4139"],"gpt_icon":0},{"id":"2468036325","title":"Bridgebio Pharma, Inc.盘中异动 股价大涨5.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2468036325","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2468036325?lang=zh_cn&edition=full","pubTime":"2024-09-19 22:22","pubTimestamp":1726755741,"startTime":"0","endTime":"0","summary":"北京时间2024年09月19日22时22分，Bridgebio Pharma, Inc.股票出现异动，股价快速拉升5.05%。Bridgebio Pharma, Inc.股票所在的生物技术行业中，整体涨幅为1.27%。其相关个股中，Exicure, Inc.、Galmed Pharmaceuticals Ltd.、Reviva Pharmaceuticals Holdings Inc C/Wts 25/12/2025涨幅较大，Galmed Pharmaceuticals Ltd.、Exicure, Inc.、Portage Biotech Inc.较为活跃，换手率分别为3468.37%、598.26%、149.93%，振幅较大的相关个股有Exicure, Inc.、Galmed Pharmaceuticals Ltd.、Reviva Pharmaceuticals Holdings Inc C/Wts 25/12/2025，振幅分别为81.66%、78.69%、52.97%。Bridgebio Pharma, Inc.公司简介：BridgeBio Pharma Inc 参与确定用于治疗孟德尔病患者的先进变革性药物，以及具有明确基因驱动因素的癌症。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024091922222198e381da&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024091922222198e381da&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BBIO","BK4588","BK4139","BK4585","BK4505"],"gpt_icon":0},{"id":"2468235034","title":"BUZZ-BridgeBio Pharma 因治疗遗传性疾病的 \"突破性疗法 \"标签而上涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2468235034","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2468235034?lang=zh_cn&edition=full","pubTime":"2024-09-17 22:10","pubTimestamp":1726582223,"startTime":"0","endTime":"0","summary":"    9月17日 - ** 药物开发商BridgeBio Pharma   股价上涨3%，至26.98美元 ** 该公司称美国食品和药物管理局已授予其实验性遗传性疾病治疗药物 \"突破性疗法 \"称号** 该标签旨在加快治疗严重疾病或未满足医疗需求的药物的开发和审查速度** 该公司正在测试一种名为 infigratinib 的药物，用于治疗患有软骨发育不全症的儿童。** 中期研究数据显示，infigratinib能使年化身高速度出现具有统计学意义的持续增长。** 包括盘中走势在内，该股今年累计下跌 32.7","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4505","BK4585","BK4588","BBIO"],"gpt_icon":0},{"id":"2466231878","title":"BUZZ--美国股票走势-Centrus Energy、Williams-Sonoma、铀矿商","url":"https://stock-news.laohu8.com/highlight/detail?id=2466231878","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2466231878?lang=zh_cn&edition=full","pubTime":"2024-09-11 23:56","pubTimestamp":1726070218,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 ))        *      Eikon 个股走势搜索字符串：[STXBZ］        *      The Day Ahead 新闻通讯：          *      The Morning News Call时事通讯：      9月11日 - 华尔街主要股指周三下跌，此前最新的通胀数据打击了美联储加大降息力度的预期，而民主党人卡马拉-哈里斯（Kamala Harris）在电视辩论后赢得美国总统职位的几率上升。美东时间11:36，道琼斯工业平均指数  下跌1.2%，至40,235.01点。标普500指数  下跌1.10%，报5435.29点；纳斯达克综合指数  下跌0.78%，报16892.726点。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CXW","PLL","VKTX","TGI","MNQmain","RLAY","ALLY","DBI","CVS","GEO","DJX","ORN","PLAY","HUM","ALB","S","NEM","SQQQ","CSIQ",".DJI","UNH","ENPH","WOOF","VRA","MAXN","DOG","MANU","BBIO","QLD","UDOW","ALTM",".SPX","WSM","AU","PLCE",".IXIC","JKS","CNC","CTLP","RJF"],"gpt_icon":1}],"profile":{"websiteUrl":"http://www.bridgebio.com","stockEarnings":[{"period":"1week","weight":-0.1035},{"period":"1month","weight":0.1624},{"period":"3month","weight":-0.0317},{"period":"6month","weight":-0.0504},{"period":"1year","weight":-0.3541},{"period":"ytd","weight":-0.3565}],"compareEarnings":[{"period":"1week","weight":-0.0349},{"period":"1month","weight":-0.0032},{"period":"3month","weight":0.0268},{"period":"6month","weight":0.0767},{"period":"1year","weight":0.2347},{"period":"ytd","weight":0.2335}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"BridgeBio Pharma, Inc.于2019年5月17日成立为特拉华州公司。他们是一个由经验丰富的药物发现者，开发者和创新者组成的团队，致力于创造改变生命的药物，从源头上瞄准特征明确的遗传性疾病。他们确定和推进转化药物治疗患有孟德尔疾病的患者，这些疾病是由单一基因缺陷引起的疾病，以及具有明确遗传驱动因素的癌症。","yearOnYearQuotes":[{"month":1,"riseRate":0.2,"avgChangeRate":-0.111762},{"month":2,"riseRate":0.4,"avgChangeRate":0.037273},{"month":3,"riseRate":0.4,"avgChangeRate":0.087947},{"month":4,"riseRate":0.2,"avgChangeRate":-0.108991},{"month":5,"riseRate":0.4,"avgChangeRate":-0.018168},{"month":6,"riseRate":0.8,"avgChangeRate":0.125791},{"month":7,"riseRate":0.5,"avgChangeRate":0.140277},{"month":8,"riseRate":0.666667,"avgChangeRate":0.029525},{"month":9,"riseRate":0.166667,"avgChangeRate":-0.060206},{"month":10,"riseRate":0.666667,"avgChangeRate":0.014306},{"month":11,"riseRate":0.666667,"avgChangeRate":0.094984},{"month":12,"riseRate":0.5,"avgChangeRate":0.035711}],"exchange":"NASDAQ","name":"BridgeBio Pharma, Inc.","nameEN":"BridgeBio Pharma, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"BridgeBio Pharma, Inc.(BBIO)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供BridgeBio Pharma, Inc.(BBIO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"BridgeBio Pharma, Inc.,BBIO,BridgeBio Pharma, Inc.股票,BridgeBio Pharma, Inc.股票老虎,BridgeBio Pharma, Inc.股票老虎国际,BridgeBio Pharma, Inc.行情,BridgeBio Pharma, Inc.股票行情,BridgeBio Pharma, Inc.股价,BridgeBio Pharma, Inc.股市,BridgeBio Pharma, Inc.股票价格,BridgeBio Pharma, Inc.股票交易,BridgeBio Pharma, Inc.股票购买,BridgeBio Pharma, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"BridgeBio Pharma, Inc.(BBIO)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供BridgeBio Pharma, Inc.(BBIO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}